Therapeutic options for metastatic castration resistant prostate cancer

has the situation improved?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Limited treatment options for Castration Resistant Prostate Cancer (CRPC) still remain a major challenge. Despite therapeutic advances, most patients with malignant PCa have a poor prognosis. Since the year 2000, we have rapidly expanded our understanding of the molecular mechanisms underlying CRPC and this has led to an unprecedented number of new drug approvals within a short span of time. Recently, four new agents namely Abiraterone Acetate, Enzalutamide, Cabazitaxel, and Radium-223 have been shown to be effective in the post-chemotherapy setting in CRPC. The continued dependency of CRPC on androgen synthesis has seen the development of a number of new anti-androgen therapies, with abiraterone acetate and Enzalutamide being the most promising discoveries. Immunotherapeutic approaches have also found their niche in PCa with Sipuleucel-T shown to be effective in minimally asymptomatic CRPC. Research focussed on bone-targeting therapies has witnessed the arrival of promising new drugs with Denosumab and Radium-223 displaying improved survival of patients with CRPC. This review briefly discusses the findings and limitations from ongoing and completed clinical trials of novel treatments and regimens. In addition, potential mechanisms of therapy resistance and future challenges are discussed.
Original languageEnglish
Title of host publicationAdvances in Drug Resistance Research
EditorsChristudas Morais
Place of PublicationNew York
PublisherNova Science Publishers
Chapter5
Pages137-154
Number of pages15
ISBN (Electronic)9781631171383
ISBN (Print)9781631171314
Publication statusPublished - 2014
Externally publishedYes

Publication series

NamePublic health in the 21st century
PublisherNova Science Publishers

Keywords

  • Prostate cancer
  • metastatic Castration Resistance Prostate Cancer
  • therapy resistance
  • Abiraterone acetate
  • Enzalutamide
  • Androgen Receptor
  • Androgen
  • Anti androgen
  • Immunotherapies
  • Bone metastasis

Fingerprint Dive into the research topics of 'Therapeutic options for metastatic castration resistant prostate cancer: has the situation improved?'. Together they form a unique fingerprint.

  • Cite this

    Jeet, V. (2014). Therapeutic options for metastatic castration resistant prostate cancer: has the situation improved? In C. Morais (Ed.), Advances in Drug Resistance Research (pp. 137-154). (Public health in the 21st century). New York: Nova Science Publishers.